Skip to main content
Premium Trial:

Request an Annual Quote

MyNeo ImmunoEngine

Precision oncology company MyNeo has released a new version of its ImmunoEngine bioinformatics platform. The update incorporates two new machine-learning algorithms, NeoMS, a transformer-based predictor based on major histocompatibility complex (MHC) ligandomic data, and NeoIM, a random-forest classifier trained to classify short peptides as either immunogenic or nonimmunogenic. The Belgian firm specializes in identifying and validating precision cancer therapies.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.